Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study.

Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study.

Publication date: Mar 20, 2024

Neurological involvement following coronavirus disease 19 (COVID-19) is thought to have a neuroinflammatory etiology. Co-ultraPEALut (an anti-inflammatory molecule) and luteolin (an anti-oxidant) have shown promising results as neuroinflammation antagonists. The aim of this study was to describe cognitive impairment in patients with post-COVID-19 treated with co-ultraPEALut. The Montreal Cognitive Assessment (MoCA), the Prospective-Retrospective Memory Questionnaire (PRMQ), the Fatigue Severity Scale (FSS), and a subjective assessment were administered at baseline and after 10 months. Patients treated with co-ultraPEALut were retrospectively compared with controls. Twenty-six patients treated with co-ultraPEALut showed a significant improvement in PRMQ (T0: 51. 94 +/- 10. 55, T1: 39. 67 +/- 13. 02, p < 0. 00001) and MoCA raw score (T0: 25. 76 +/- 2. 3, T1: 27. 2 +/- 2, p 0. 0260); the MoCA-adjusted score and the FSS questionnaires also showed an improvement, even though it was not statistically significant; and 80. 77% of patients reported a subjective improvement. In the control subjects (n = 15), the improvement was not as pronounced (PRMQ T0: 45. 77 +/- 13. 47, T1: 42. 33 +/- 16. 86, p 0. 2051; FSS T0: 4. 95 +/- 1. 57, T1: 4. 06 +/- 1. 47, p 0. 1352). Patients treated with co-ultraPEALut and corticosteroids were not statistically different from those treated with co-ultraPEALut alone. Neuro-post-COVID-19 patients treated with co-ultraPEALut scored better than controls in MoCA and PRMQ questionnaires after 10 months: this may support the importance of neuroinflammation modulation for neuro-long-COVID-19.

Open Access PDF

Concepts Keywords
Coronavirus co-ultraPEALut
Covid cognitive impairment
Improvement long-COVID-19
Neuroinflammation neuro-long-COVID-19


Type Source Name
disease MESH Cognitive Impairment
disease MESH SARS-CoV-2 Infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH etiology
disease MESH neuroinflammation
drug DRUGBANK Tropicamide
drug DRUGBANK Trestolone
disease MESH long COVID
disease VO organization
disease MESH clinical relevance
disease IDO entity
disease MESH syndrome
disease MESH sequelae
disease MESH infection
drug DRUGBANK Coenzyme M
disease MESH cytokine storm
disease MESH inflammation
drug DRUGBANK Palmidrol
disease IDO intervention
disease MESH vascular dementia
disease MESH ischemic stroke
disease MESH olfactory impairment
drug DRUGBANK Polydatin
disease IDO production
disease MESH psychiatric disorders
disease MESH dementia
disease MESH schizophrenia
disease MESH bipolar disorder
disease IDO symptom
disease VO report
disease IDO blood
disease IDO history
disease MESH defects
drug DRUGBANK Cysteamine
disease VO frequency
drug DRUGBANK Prednisone
disease VO dose
disease VO USA
disease VO time

Original Article

(Visited 1 times, 1 visits today)